Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 310

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 310
---
 by the Company’s valuation allowance, and therefore did not result in a material impact on the Company’s financial results for the period.

3. Marketable Securities 

The following tables summarize the amortized cost and estimated fair value of the Company’s current and noncurrent marketable securities (in thousands):September 30, 2025AmortizedCost UnrealizedGainsUnrealizedLosses Fair ValueMarketable securities, current:U.S. Treasury securities$130,095 $213 $— $130,308 Commercial paper28,989 2 (5)28,986 Government agency securities24,477 22 — 24,499 Corporate debt13,701 5 (1)13,705 Total marketable securities, current197,262 242 (6)197,498 Marketable securities, noncurrent:U.S. Treasury securities57,128 172 (9)57,291 Government agency securities19,359 27 (6)19,380 Total marketable securities, noncurrent76,487 199 (15)76,671 Total marketable securities$273,749 $441 $(21)$274,169 December 31, 2024Amortized Cost Unrealized Gain Unrealized Loss Fair Value Marketable securities, current:U.S. Treasury securities$55,154 $176 $— $55,330 Government agency securities31,198 62 (1)31,259 Corporate debt17,205 22 — 17,227 Commercial paper5,931 3 — 5,934 Total marketable securities, current109,488 263 (1)109,750 Marketable securities, noncurrent:U.S. Treasury securities15,266 83 — 15,349 Government agency securities5,133 23 — 5,156 Total marketable securities, noncurrent20,399 106 — 20,505 Total marketable securities$129,887 $369 $(1)$130,255 The Company has determined that there were no material changes in the credit risk, therefore the Company has not recognized any allowance for credit losses on its debt securities. As of September 30, 2025, 

F-9

the Company holds marketable securities with an aggregate fair value of $76.7 million that had remaining maturities between one and two years